Objective: Fibroblast Activation Protein (FAP), an enzyme structurally related to dipeptidyl peptidase-4 (DPP-4), has garnered interest as a potential metabolic drug target due to its ability to cleave and inactivate FGF-21 as well as other peptide substrates. Here we investigated the metabolic importance of FAP for control of body weight and glucose homeostasis in regular chow-fed and high fat diet-fed mice. Methods: FAP enzyme activity was transiently attenuated using a highly-specific inhibitor CPD60 and permanently ablated by genetic inactivation of the mouse Fap gene. We also assessed the FAP-dependence of CPD60 and talabostat (Val-boroPro), a chemical inhibitor reportedly targeting both FAP and dipeptidyl peptidase-4 Results: CPD60 robustly inhibited plasma FAP activity with no effect on DPP-4 activity. Fap gene disruption was confirmed by assessment of genomic DNA, and loss of FAP enzyme activity in plasma and tissues. CPD60 did not improve lipid tolerance but modestly improved acute oral and intraperitoneal glucose tolerance in a FAP-dependent manner. Genetic inactivation of Fap did not improve glucose or lipid tolerance nor confer resistance to weight gain in male or female Fap À/À mice fed regular chow or high-fat diets. Moreover, talabostat markedly improved glucose homeostasis in a FAP-and FGF-21-independent, DPP-4 dependent manner. Conclusion: Although pharmacological FAP inhibition improves glucose tolerance, the absence of a metabolic phenotype in Fap À/À mice suggest that endogenous FAP is dispensable for the regulation of murine glucose homeostasis and body weight. These findings highlight the importance of characterizing the specificity and actions of FAP inhibitors in different species and raise important questions about the feasibility of mouse models for targeting FAP as a treatment for diabetes and related metabolic disorders.
INTRODUCTION
The metabolic roles of peptide hormones with endocrine activity have received considerable attention in the context of the rising incidence of diabetes and obesity. Notably, multiple gut hormones secreted from enteroendocrine cells control islet function and glucose homeostasis, and a subset of these hormones also regulate food intake, body weight, and lipid metabolism [1, 2] . Furthermore, some members of the circulating fibroblast growth factor family, exemplified by fibroblast growth factor 21 (FGF-21), also exhibit hormone-like activity, and have been evaluated as therapeutic candidates for the treatment of diabetes, obesity, and non-alcoholic steatohepatitis [3, 4] . The favorable metabolic actions of several gut hormones, notably glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like-peptide-1 (GLP-1), have received considerable attention, and GLP-1 receptor agonists have been developed for the therapy of type 2 diabetes (T2D) and obesity [5] .
A conserved feature shared by many peptide hormones is their short biological half-life, reflecting extraction and degradation by peripheral organs, urinary clearance, as well as enzymatic inactivation. Notably, N-terminal peptide cleavage by dipeptidyl peptidase-4 (DPP-4), the most extensively studied member of the DPP-4 activity and/or structure homologue (DASH) proteins [6] , plays a critical role in terminating hormone action [7] . DPP-4 cleaves and inactivates GLP-1, oxyntomodulin, pituitary adenylate cyclase-activating peptide (PACAP), and glucose-dependent insulinotropic polypeptide (GIP), highlighting its key role in control of glucose homeostasis [8] . The biological importance of DPP-4 for control of islet function and glucose homeostasis has been demonstrated using mouse genetics, as well as through analysis of the biological activity of highly selective DPP-4 inhibitors in animals and humans [7, 9, 10] . Notably, genetic elimination of Dpp4 in mice improves glucose homeostasis via potentiation of gut hormone action [11, 12] , findings mirrored by administration of small molecule highly selective DPP-4 inhibitors [7, 9, 10] .
The therapeutic success of DPP-4 inhibitors for the treatment of T2D has stimulated interest in the metabolic actions of structurally-related DASH enzymes [6, 7] , including fibroblast activation protein (FAP)/ seprase, a member of the DASH family with over 50% amino acid sequence identity with DPP-4 [13] . Intriguingly, both DPP-4 and FAP were first studied as candidate regulators of tumor cell growth, with elevated FAP expression detected within activated stromal fibroblasts of human epithelial cancers [14] . Both DPP-4 and FAP exhibit overlapping dipeptidyl peptidase activity and cleave a subset of similar substrates ex vivo [15] . In contrast to DPP-4, FAP also has a unique endopeptidase activity with a GlyePro specificity [16, 17] . Furthermore, both DPP-4 and FAP exert activity as cell-anchored enzymes and via circulating soluble forms that retain enzyme activity [18, 19] . FAP enzymatic activity is detectable, albeit at relatively low levels, in metabolically active tissues such as muscle, pancreas, and adipose tissue [19e21] . The observation that talabostat improves glucose homeostasis in mice was linked to FAP inhibition and potentiation of fibroblast growth factor-21 (FGF-21) activity [22] . However, early on, talabostat had been shown to be a potent DPP4 inhibitor [23] with glucose-lowering activity [24, 25] . In fact, talabostat is w20,000-fold more potent as an inhibitor of DPP-4 (Ki w 5 pM) than of FAP (Ki w 100 nM) [26] . Hence, ascribing anti-diabetic activities of talabostat to the inhibition of FAP can only be done in the absence of or concomitant inhibition of DPP-4 activity. The emerging metabolic importance of FAP, and its overlapping structural and functional relationship to DPP-4, prompted us to further assess the importance of endogenous FAP in the control of glucose and lipid homeostasis. We therefore examined the effects of a potent and specific FAP inhibitor, (S)-N-(2-(2-Cyano-4,4-difluoropyrrolidin-1-yl)-2-oxoethyl)-quinoline-4-carboxamide [27] herein referred to as Compound 60 (CPD60), and found that it does indeed improve glucose tolerance, albeit modestly. In contrast, Fap À/À mice did not exhibit improved glucose control, or resistance to weight gain after prolonged high fat feeding. Furthermore, talabostat's anti-diabetic activities were independent of FGF21 or FAP. Taken together, our findings indicate that murine FAP is not a critical determinant of islet function, glucose homeostasis, weight gain, and the metabolic response to high fat feeding in mice.
MATERIALS AND METHODS

Animals
All animal studies were carried out according to protocols approved by Sinai Health System and The Centre for Phenogenomics (TCP, Toronto, Ontario, Canada). For studies using C57BL/6J mice, male animals aged 12 weeks or older were obtained from the in-house breeding colony at TCP. All mice were housed under specific pathogen-free conditions in ventilated microisolator cages and maintained on a 12-h light/dark cycle with free access to food and water unless otherwise noted. To account for sexual dimorphism, both males and females were studied in parallel for most experiments.
/Ddr) mice on a C57BL/6J background were generated at TCP by embryonic pronuclear microinjection of Cas9 mRNA and a single guide RNA with a spacer sequence of CCAC-TAAAGCAAGCGCAGCC, which resulted in a 5 bp deletion (GCGCT) in exon 2 at approximate position 62,573,481 bp (GRCm38) (confirmed by Sanger sequencing). This mutation is predicted to cause amino acid sequence changes after residue 15 and early truncation 17 amino acids later. Genotyping was performed using the following primers: Primer Fap-F (5 0 /3 0 ): TCAAAAGCTCTGTGGGGAA; Primer Fap-R (5 0 /3 0 ): GGTTTGGAATAATAGGGGCATAG. These primers amplify a 931 bp product, which, following digestion with Mwo1 (N.E.B. product #R0573S), yields a 794bp DNA fragment. In contrast, Mwo1 does not cleave a PCR product generated from homozygous knockout mouse DNA (see Figure S1 ).
Fgf21
À/À mice Fgf21 À/À (Fgf21 tm1.1Djm ; MGI:4354163) mice were re-derived at TCP after being obtained from the laboratory of Steven A. Kliewer and originally developed by David J. Mangelsdorf [28] . Genotyping was performed using the following primers: Primer F21SeqF1 (5 0 /3 0 ): CCTCCAGATTTAGGAGTGCAGA; Primer F21GREV6-1 (5 0 /3 0 ): GAA-GACAGCCAGCAGCAGTCG; Primer F21NeoRev3 (5 0 /3 0 ): GCATCGCCTTCTATCGCCTTCTTG. Together, these primers amplify a 500bp band from DNA corresponding to a WT allele, and a 300bp band from DNA corresponding to a Fgf21 mutant allele.
Dpp4
À/À mice Dpp4 À/À (CD26 À/À ) mice were maintained in the Drucker lab and genotyped as described [11, 29] . [19] . For plasma DPP-4 activity, H-Gly-Pro-AMC HBr (Bachem #I-1225) was used as a substrate and plasma samples assayed in a 20-minute room-temperature timed protocol as described previously [30] . A single dose of CPD60 (20 mg/ kg) produced sustained (more than 75%) inhibition of FAP activity for at least 12 h ( Figure 1A and unpublished observations).
2.4. Magnetic resonance imaging (MRI), indirect calorimetry, and locomotor activity For assessment of body composition, a whole body magnetic resonance analyzer was used (EchoMRI-100, Echo Medical Systems).
Measures of O 2 consumption, CO 2 production, respiratory quotient, heat production, and physical activity were obtained after 2 days of acclimatization and 1 day of measurement using a Rodent Oxymax system (Columbus Instruments). Food intake was obtained manually by weighing food before and after 3 days in metabolic cages.
Gene expression analysis
RNA was isolated from various tissues according to the manufacturer's protocol (Tri-Reagent, Molecular Research Center Inc., Cincinnati, OH). Homogenization was performed in a medium-throughput manner using the TissueLyser II (Quiagen) with stainless steel beads. Firststrand cDNA was synthesized using SuperScript III reverse transcriptase (Invitrogen) and random hexamers. Quantitative polymerase chain reaction (qPCR) was performed using the QuantStudio 5 Real-Time PCR System (ThermoFisher) and TaqMan Gene Expression Assays and Universal PCR Master Mix (Applied Biosystems) using the following TaqMan primers: 
Data analysis
All data were graphed and analyzed using GraphPad Prism, version 7.0d. Data are presented as mean þ/À SD. Analyses performed included non-linear regression, ANOVA, 2-way ANOVA, two-tailed ttest, and paired t-test where appropriate. A P value less than 0.05 was considered to be statistically significant.
RESULTS
Pharmacological FAP inhibition improves glucose tolerance
To study the effects of acute FAP inhibition on glucose tolerance, we used a relatively selective FAP inhibitor [27, 31] , previously demonstrated to completely suppress FAP activity in mouse plasma [32] . When administered orally, CPD60 robustly inhibited plasma FAP enzymatic activity as early as 15 min post-gavage ( Figure 1A ). In contrast, the same doses of CPD60 had no effect on plasma DPP-4 activity ( Figure 1B ). Nevertheless, despite marked inhibition of FAP activity, CPD60 only modestly reduced glycemic excursion during oral and intraperitoneal glucose tolerance tests in a dose-dependent manner (Figure 1CeD ), without concomitant changes in plasma levels of insulin and glucagon. Insulin sensitivity approximated by insulin tolerance testing was not different following administration of CPD60 (Figure 1EeG ). Moreover, plasma triglycerides assessed following olive oil gavage were not different in the presence or absence of CPD60 ( Figure 1H [15, 22] . Accordingly, we assessed No evidence for upregulation of these mRNA transcripts in Fap À/À mouse tissues was observed ( Figure S8 ). Analysis of relative expression levels reported according to uncorrected CT values indicated the highest levels of Fap mRNA expression within muscle and adipose tissues ( Figure S9 ). Hence, CPD60 requires FAP to acutely improve oral glucose tolerance.
Talabostat inhibits DPP-4 enzymatic activity and requires
Dpp4 to improve glucose tolerance The finding that complete genetic elimination of FAP activity produces no substantial metabolic phenotype contrasts with the metabolic benefits previously ascribed to pharmacological FAP inhibition with talabostat (Val-boroPro) [22] . Talabostat has been reported to potentiate FGF-21 activity, through actions ascribed to enzymatic FAP inhibition [22, 33] ; however, talabostat is first and foremost a DPP4 inhibitor and therefore also exerts anti-diabetic activity via inhibition of DPP-4 [23, 25, 26, 34, 35] . To reconcile these findings, we compared the acute actions of talabostat in Fgf21 À/À , Dpp4 À/À , and Fap À/À mice and their littermate controls. Notably, talabostat improved glucose tolerance and increased plasma insulin levels in Fgf21 À/À mice (Figure 6AeC ). In contrast, talabostat was highly effective at lowing glucose excursions in Dpp4 þ/þ but not in Dpp4 À/À mice ( Figure 6D , E), without further augmentation of plasma insulin levels ( Figure 6F ). Interestingly, talabostat acutely improved glucose homeostasis in both Fap þ/þ and Fap À/À mice, without further augmentation of insulin levels ( Figure 6GeI ). Consistent with these findings, talabostat potently inhibited plasma DPP-4 activity in all groups and had little effect on FAP activity at the dose used; in contrast CPD60 suppressed FAP, but not DPP-4 activity (Figure 6JeK ). Furthermore, no genotype or drugdependent changes in total immunoreactive FGF-21 levels were detected in the fasted state ( Figure 6L ). Taken together, these results indicate that germline genetic elimination of Fap in mice is not associated with improvements in glucose control or resistance to dietinduced obesity. Furthermore, the metabolic benefits ascribed to talabostat administration likely reflect actions predominantly arising from potent inhibition of DPP-4, and not FAP activity.
DISCUSSION
Our current experiments directed at elucidating the metabolic importance of FAP were motivated by recent studies supporting a role for FAP in control of glycemia and body weight [22] , together with an extensive literature highlighting the metabolic importance of the structurally and functionally related DASH enzyme, DPP-4 [7, 9, 10] . Notably, plasma levels of both DPP-4 and FAP activity are increased in human subjects with T2D [36, 37] , consistent with the possibility that increased expression of one or both enzymes contributes to the development of dysglycemia via degradation of glucoregulatory substrates. Indeed, DPP-4 has been extensively validated, in studies ranging from mouse genetics to clinical trials using DPP-4 inhibitors, as an essential enzyme regulating glucose homeostasis and islet function [7,9e11] . Several previous studies linking inhibition of FAP activity to reduction of glucose and body weight in mice [22] employed talabostat, a nonselective FAP inhibitor, that also inhibits other members of the structurally related DASH enzyme family, especially DPP4 [34] . Intriguingly, the favorable metabolic activity of talabostat, including reduction of glucose and body weight, and augmentation of circulating levels of FGF-21, was reported to be predominantly evident in mice with diet-induced obesity, and markedly attenuated in lean euglycemic mice [22] . Here we demonstrate that acute reduction of FAP activity, using CPD60, a highly selective FAP inhibitor [27, 32] , was associated with a modest but significant improvement in oral and intraperitoneal glucose tolerance without affecting insulin or glucagon levels. In contrast, complete elimination of FAP activity in Fap À/À mice was not associated with changes in glucose tolerance, islet hormones, or insulin sensitivity, even under conditions of prolonged HFD-feeding. Hence, collectively, our data suggest that, in contrast to the favorable metabolic phenotype described for Dpp4 À/À mice [11] , genetic loss of Fap is not essential for control of metabolic homeostasis in mice. One simple explanation for the favorable metabolic actions of talabostat in obese mice [22] , vs. the modest actions of the relatively FAPselective CPD60, is the potent inhibition of DPP-4 activity by talabostat [25] . Indeed, our current findings verify that talabostat at the dose previously utilized [22] robustly reduces DPP-4 activity and not FAP activity, and fails to further improve glucose tolerance in Dpp4 À/À mice. Notably, DPP-4 and FAP are co-expressed on several cell types [38] , and have been shown to cleave an overlapping set of regulatory peptides, including neuropeptide Y (NPY), peptide YY, B-type natriuretic peptide and substance P [15] . FAP and DPP-4 also physically interact to form a heteromeric complex that retains functional enzyme activity [38, 39] . Hence, it seems reasonable to explore the therapeutic potential of dual enzyme inhibitors for the treatment of metabolic disease,
given the close inter-dependent structural and functional overlapping interactions demonstrated for FAP and DPP-4. Enthusiasm for the exploration of single or dual FAP inhibitors as a therapeutic approach for treatment of metabolic disorders stems in part from the role of FAP in the cleavage and inactivation of FGF-21. Indeed, genetic ablation, immunodepletion, or pharmacological inhibition of FAP activity, with inhibitors such as CPD60, markedly inhibits the cleavage of human FGF-21 [32, 33] . Nevertheless, the importance and biological activity of N-terminally cleaved forms of FGF-21 and their relationship to relative levels of total circulating immunoreactive FGF-21 has not been extensively assessed in humans. Insulin levels during OGTT. D) Glucagon levels during OGTT. 2-way ANOVA revealed no significant differences in hormone response to drug within genotypes. AUC analyses were tested using paired t-tests. *P < 0.05.
Fgf21 mRNA were upregulated in mice following high fat feeding. These differences in nutrient control of Fgf21 expression may reflect species-specific differences and experimental conditions, including diets, genetic background, age, and sex of mice that differ in various studies across laboratories. The generation and phenotypic characterization of Fap À/À mice has been described over 15 years ago, with reports of normal growth and development in the setting of complete absence of Fap protein and enzyme activity [44] . More recently, an independent line of Fap À/À mice generated on the C57BL/6 background for studies of cancer biology was reported to exhibit normal levels of plasma glucose, pancreatic weight, and pancreatic histology, although dynamic metabolic testing was not reported [45] . The findings reported here of normal glucose homeostasis and body weight in RC-and HFD-fed Fap À/À mice strongly suggest that FAP is not essential for the adaptive metabolic response to energy excess in mice.
CONCLUSIONS AND LIMITATIONS
Our studies in mice have several caveats, limiting extrapolation to human biology. First, the mouse FAP protein differs structurally and functionally from human FAP [19] . Although circulating FAP enzymatic , and vehicle-or CPD60-treated C57BL6 mice. Due to the design of the crossover studies, data were analyzed using paired t-test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. activity is relatively higher in mouse vs. human plasma [19] , mouse FAP exhibited a lower catalytic activity, compared to human FAP, ex vivo [31] . Furthermore, it is possible that additional species-specific differences in the structure of putative metabolically active FAP substrates, beyond FGF-21, may further complicate interpretation of FAP biology in mice vs. humans. Notably, commercially available assays for measurement of FGF-21 in mice do not allow reliable discrimination of cleaved vs. intact forms of FGF-21, precluding definitive ascertainment of whether FAP cleaves FGF-21 in the studies reported here. Additionally, we studied mice with complete elimination of Fap in all tissues, and developmental adaptations and compensation in response to global germline elimination of FAP may modify the biological phenotypes arising from loss of FAP in one or more tissues. Notably, acute transient FAP inhibition with CPD60, a short-acting FAP inhibitor, does improve oral and intraperitoneal glucose tolerance via currently unknown mechanisms, hence a role for more sustained pharmacological FAP inhibition as a therapeutic opportunity for metabolic disorders such as diabetes cannot be excluded by our data. Taken together, these findings have relevance for the design of preclinical experimental paradigms to assess the therapeutic potential of FAP in the control of metabolism and energy homeostasis.
DISCLOSURES
The authors report no disclosures relevant to the study of mouse FAP biology.
